12:00 AM
 | 
May 28, 2012
 |  BC Week In Review  |  Company News  |  Other News

Halo Therapeutics musculoskeletal news

Halo received $1.1 million from 12 not-for-profits comprising a mix of grant money and notes that will be repaid with a fixed return should undisclosed pre-defined events occur. Halo will use the funds for its Phase II trial of HT-100 in Duchenne muscular dystrophy (DMD) slated to begin next half. HT-100...

Read the full 241 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$30 USD
More Info >